Contact this trialFirst, we need to learn more about you.
PD-L1 Inhibitor
Copanlisib + Durvalumab for Lung Cancer
Recruiting1 awardPhase 1
Lexington, Kentucky
This trial is testing whether adding Copanlisib to Durvalumab will help treat unresectable stage III NSCLC patients who have already undergone chemoradiation.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.